<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04136873</url>
  </required_header>
  <id_info>
    <org_study_id>CVL-231-SCH-001</org_study_id>
    <nct_id>NCT04136873</nct_id>
  </id_info>
  <brief_title>A Multiple Ascending Dose Trial of CVL-231 in Subjects With Schizophrenia</brief_title>
  <official_title>A Phase 1B Trial To Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Ascending Doses of CVL-231 in Subjects With Schizophrenia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cerevel Therapeutics, LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cerevel Therapeutics, LLC</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this trial is to investigate the safety, tolerability, pharmacokinetics (PK), and&#xD;
      pharmacodynamics (PD) of CVL-231 following multiple-dose oral administration in subjects with&#xD;
      schizophrenia.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 15, 2019</start_date>
  <completion_date type="Actual">June 3, 2021</completion_date>
  <primary_completion_date type="Actual">May 7, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Treatment Emergent Adverse Events (TEAEs)</measure>
    <time_frame>Up to Day 72</time_frame>
    <description>Includes Incidence of Significant ECG Abnormalities Occurring Post-Baseline, significant changes in Vital signs (Systolic and Diastolic blood pressures, heart rate, respiratory rate and body temperature), and changes in laboratory measures (hematology, serum chemistry and urinalysis)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of suicidality as assessed by Columbia-Suicide Severity Rating Scale(C-SSRS)</measure>
    <time_frame>Up to Day 72</time_frame>
    <description>The C-SSRS rates an individual's degree of suicidal ideation (SI) on a scale, ranging from &quot;wish to be dead&quot; to &quot;active suicidal ideation with specific plan and intent.&quot; The scale identifies SI severity and intensity, which may be indicative of an individual's intent to commit suicide. C-SSRS SI severity subscale ranges from 0 (no SI) to 5 (active SI with plan and intent).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from Baseline of Simpson-Angus Scale (SAS) Results</measure>
    <time_frame>Up to Day 72</time_frame>
    <description>Evaluating Extrapyramidal symptoms using the SAS. The SAS consists of a list of 10 symptoms of parkinsonism (gait, arm dropping, shoulder shaking, elbow rigidity, wrist rigidity, head rotation, glabella tap, tremor, salivation, and akathisia). Each item is rated on a 5-point scale, with a score of 0 representing absence of symptoms and a score of 4 representing a severe condition. The SAS total score is the sum of the scores for all 10 items.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from Baseline of Abnormal Involuntary Movement Scale (AIMS) Results</measure>
    <time_frame>Up to Day 72</time_frame>
    <description>The AIMS assessment consists of 10 items describing symptoms of dyskinesia. Facial and oral movements (items 1 through 4), extremity movements (items 5 and 6), and trunk movements (item 7) are observed unobtrusively while the subject is at rest, and the investigator also makes global judgments on the subject's dyskinesias (items 8 through 10). Each item is rated on a 5-point scale, with a score of 0 representing absence of symptoms (for item 10, no awareness), and a score of 4 indicating a severe condition (for item 10, awareness, severe distress). In addition, the AIMS includes 2 yes/no questions that address the subject's dental status.&#xD;
The AIMS Movement Rating Score is defined as the sum of items 1 through 7 (ie, items 1 through 4, facial and oral movements; items 5 and 6, extremity movements; and item 7, trunk movements).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from Baseline of Barnes Akathisia Rating Scale (BARS) Results</measure>
    <time_frame>Up to Day 72</time_frame>
    <description>Evaluating Extrapyramidal symptoms using the BARS. The BARS consists of 4 items related to akathisia: objective observation of akathisia by the investigator, subjective feelings of restlessness by the subject, subjective distress due to akathisia, and global clinical assessment of akathisia. The first 3 items are rated on a 4-point scale, with a score of 0 representing absence of symptoms and a score of 3 representing a severe condition. The global clinical evaluation is made on a 6-point scale, with a score of 0 representing absence of symptom and a score of 5 representing severe akathisia.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Single-dose: Area under the plasma concentration vs. time curve (AUC) for CVL-231 and Metabolite (PF-06892787)</measure>
    <time_frame>Day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Single-dose: Peak Plasma Concentration (Cmax) for CVL-231 and Metabolite (PF-06892787)</measure>
    <time_frame>Day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Single-dose: Time to Maximum Concentration (Tmax) for CVL-231 and Metabolite (PF-06892787)</measure>
    <time_frame>Day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Single-dose: Metabolite to parent ratio for Cmax for CVL-231 and Metabolite (PF-06892787)</measure>
    <time_frame>Day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Single-dose: Metabolite to parent ratio for AUC tau for CVL-231 and Metabolite (PF-06892787)</measure>
    <time_frame>Day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Multiple-dose: Steady state CVL-231 Peak Plasma Concentration (Cmax) for CVL-231 and Metabolite (PF-06892787)</measure>
    <time_frame>Days 14 and/or 28 and/or 36</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Multiple-dose: Time to Maximum Concentration (Tmax) for CVL-231 and Metabolite (PF-06892787)</measure>
    <time_frame>Days 14 and/or 28 and/or 36</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Multiple-dose: Trough plasma concentration (Ctrough) for CVL-231 and Metabolite (PF-06892787)</measure>
    <time_frame>Days 14 and/or 28 and/or 36</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Multiple-dose: Minimum blood plasma concentration (Cmin) for CVL-231 and Metabolite (PF-06892787)</measure>
    <time_frame>Days 14 and/or 28 and/or 36</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Multiple-dose: Area under the plasma concentration-time curve (AUCτ) for CVL-231 and Metabolite (PF-06892787)</measure>
    <time_frame>Days 14 and/or 28 and/or 36</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Multiple-dose: Area under the plasma concentration-time curve from time zero to infinity (AUCinf) for CVL-231 and Metabolite (PF-06892787)</measure>
    <time_frame>Days 14 and/or 28 and/or 36</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Multiple-dose: Apparent Total Clearance of Drug from plasma: CL/F for CVL-231</measure>
    <time_frame>Days 14 and/or 28 and/or 36</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Multiple-dose: Steady-state average plasma drug concentration: Css for CVL-231 and Metabolite (PF-06892787)</measure>
    <time_frame>Days 14 and/or 28 and/or 36</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Multiple-dose: Peak Trough Ratio (PTR) for CVL-231 and Metabolite (PF-06892787)</measure>
    <time_frame>Days 14 and/or 28 and/or 36</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Multiple-dose: Accumulation ratio calculated from Cmax,ss and Cmax after single dosing (Rac, Cmax) for CVL-231 and Metabolite (PF-06892787)</measure>
    <time_frame>Days 14 and/or 28 and/or 36</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Multiple-dose: Accumulation ratio calculated from AUCτ,ss and AUCτ after single dosing (Rac, AUC) for CVL-231 and Metabolite (PF-06892787)</measure>
    <time_frame>Days 14 and/or 28 and/or 36</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Multiple-dose: Elimination half-life (t½) for CVL-231 and Metabolite (PF-06892787)</measure>
    <time_frame>Day 14-17 and/or Day 28-31</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Multiple-dose: Elimination rate constant (kel) for CVL-231 and Metabolite (PF-06892787)</measure>
    <time_frame>Day 14-17 and/or Day 28-31</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Multiple-dose: Ae (amount eliminated unchanged in urine) for CVL-231 and Metabolite (PF-06892787)</measure>
    <time_frame>Days 14 and/or 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Multiple-dose: Renal clearance for parent only for CVL-231</measure>
    <time_frame>Days 14 and/or 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Multiple-dose: Metabolite to parent ratio for Cmax for CVL-231 and Metabolite (PF-06892787)</measure>
    <time_frame>Days 14 and/or 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Multiple-dose: Metabolite to parent ratio for AUCtau for CVL-231 and Metabolite (PF-06892787)</measure>
    <time_frame>Days 14 and/or 28</time_frame>
  </secondary_outcome>
  <number_of_arms>14</number_of_arms>
  <enrollment type="Actual">130</enrollment>
  <condition>Schizophrenia</condition>
  <arm_group>
    <arm_group_label>Part A: 5 mg QD CVL-231</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Oral Dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A: 5 mg QD Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matching Placebo; Oral Dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A: 10 mg QD CVL-231</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Oral Dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A: 10 mg QD Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matching Placebo; Oral Dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A: 20 mg QD CVL-231</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Oral Dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A: 20 mg QD Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matching Placebo; Oral Dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A: 5-10-20 mg BID CVL-231</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Oral Dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A: 5-10-20 mg BID Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matching Placebo; Oral Dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A: 30 mg QD CVL-231</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Oral Dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A: 30 mg QD Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matching Placebo; Oral Dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B 30 mg QD CVL-231</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Oral Dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B 30 mg QD Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matching Placebo; Oral Dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B 20 mg BID CVL-231</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Oral Dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B 20 mg BID Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CVL-231</intervention_name>
    <description>CVL-231</description>
    <arm_group_label>Part A: 10 mg QD CVL-231</arm_group_label>
    <arm_group_label>Part A: 20 mg QD CVL-231</arm_group_label>
    <arm_group_label>Part A: 30 mg QD CVL-231</arm_group_label>
    <arm_group_label>Part A: 5 mg QD CVL-231</arm_group_label>
    <arm_group_label>Part A: 5-10-20 mg BID CVL-231</arm_group_label>
    <arm_group_label>Part B 20 mg BID CVL-231</arm_group_label>
    <arm_group_label>Part B 30 mg QD CVL-231</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Matching Placebo</intervention_name>
    <description>Placebo matching CVL-231</description>
    <arm_group_label>Part A: 10 mg QD Placebo</arm_group_label>
    <arm_group_label>Part A: 20 mg QD Placebo</arm_group_label>
    <arm_group_label>Part A: 30 mg QD Placebo</arm_group_label>
    <arm_group_label>Part A: 5 mg QD Placebo</arm_group_label>
    <arm_group_label>Part A: 5-10-20 mg BID Placebo</arm_group_label>
    <arm_group_label>Part B 20 mg BID Placebo</arm_group_label>
    <arm_group_label>Part B 30 mg QD Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Subjects with a primary diagnosis of schizophrenia per DSM-5, as confirmed by the&#xD;
             MINI.&#xD;
&#xD;
          2. Subjects with the following scores on the PANSS at time of signing ICF and at Day -1:&#xD;
             • Positive Subscale 7 (hostility) ≤3 (normal to moderate) • General Psychopathology&#xD;
             Subscale 8 (uncooperativeness) ≤3 (normal to moderate)&#xD;
&#xD;
          3. Subjects with the following scores (normal to mild symptoms) at time of signing ICF&#xD;
             and at Day -1: • All individual items of the Modified SAS (M-SAS) &lt;2 • All individual&#xD;
             items (Items 1-7) of the Abnormal Involuntary Movement Scale (AIMS) &lt;2 • Clinical&#xD;
             global assessment item of the Barnes Akathisia Rating Scale (BARS) &lt;3&#xD;
&#xD;
          4. Body mass index of 17.5 to 38.0 kg/m2 and a total body weight &gt;50 kg (110 lbs).&#xD;
&#xD;
        Cohorts 1 Through 5 (Part A):&#xD;
&#xD;
        Subjects are eligible to be included in trial (Cohorts 1 through 5) only if all of the&#xD;
        following additional criteria apply:&#xD;
&#xD;
          1. Male and female subjects, ages 18 to 50 years, inclusive.&#xD;
&#xD;
          2. Subjects with a score on the CGI-S ≤4 (normal to moderately ill) at time of signing&#xD;
             ICF and at Day -1.&#xD;
&#xD;
          3. Subjects with a PANSS total score of ≤80 at the time of signing ICF and at Day -1.&#xD;
&#xD;
        Cohort 6 (Part B):&#xD;
&#xD;
        Subjects are eligible to be included in trial (Cohort 6) only if all of the following&#xD;
        additional criteria apply:&#xD;
&#xD;
          1. Male and female subjects, ages 18 to 55 years, inclusive.&#xD;
&#xD;
          2. Subjects with a score on the CGI-S ≥4 (moderately to severely ill) at time of signing&#xD;
             ICF and at Day -1.&#xD;
&#xD;
          3. Subjects with a PANSS total score of ≥80 at the time of signing ICF and at Day -1.&#xD;
             Additionally, subjects must meet a score of ≥4 (moderate or greater) for ≥2 of the&#xD;
             following Positive Scale items at the time of signing ICF and at Day -1:&#xD;
&#xD;
               -  Positive Scale 1 (delusions)&#xD;
&#xD;
               -  Positive Scale 2 (conceptual disorganization)&#xD;
&#xD;
               -  Positive Scale 3 (hallucinatory behavior)&#xD;
&#xD;
               -  Positive Scale 6 (suspiciousness/persecution)&#xD;
&#xD;
          4. Subjects with a history of relapse and/or exacerbation of symptoms when not receiving&#xD;
             antipsychotic treatment, excluding the current episode.&#xD;
&#xD;
          5. Subjects must be experiencing an acute exacerbation or relapse of symptoms, with onset&#xD;
             less than 2 months prior to signing ICF.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Subjects with a current DSM-5 diagnosis other than schizophrenia including, but not&#xD;
             limited to, mental retardation; schizoaffective disorder; schizophreniform disorder;&#xD;
             psychotic depression; major depressive disorder; bipolar disorder; post-traumatic&#xD;
             stress disorder; generalized anxiety disorder, obsessive compulsive disorder, eating&#xD;
             disorders (bulimia, anorexia), or other anxiety disorders as a primary diagnosis&#xD;
             (subjects with anxiety symptoms secondary to schizophrenia are allowed); delirium,&#xD;
             dementia, amnestic, or other cognitive disorders. Also, subjects with borderline,&#xD;
             paranoid, histrionic, schizotypal, schizoid, or antisocial personality disorder.&#xD;
&#xD;
          2. Subjects with schizophrenia who were considered resistant/refractory to antipsychotic&#xD;
             treatment by history or who had a history of failure to respond to clozapine or&#xD;
             response to clozapine treatment only.&#xD;
&#xD;
          3. Subjects with EPS being treated with a medication that required dose modification&#xD;
             and/or new treatment within 6 months prior to signing ICF.&#xD;
&#xD;
          4. Subjects with a current history of significant pulmonary, gastrointestinal, renal,&#xD;
             hepatic, metabolic, endocrine (including newly diagnosed diabetes mellitus or subjects&#xD;
             with known diabetes mellitus with glycosylated hemoglobin (HbA1c)&gt;7.5%),&#xD;
             hematological, immunological, psychiatric (excluding schizophrenia), or neurological&#xD;
             disease.&#xD;
&#xD;
          5. Subjects with a current or past history of significant cardiovascular disease.&#xD;
&#xD;
          6. Subjects who experienced acute depressive symptoms within the past 30 days.&#xD;
&#xD;
          7. Subjects with epilepsy or a history of seizures, except for a single seizure episode,&#xD;
             eg, a childhood febrile seizure, or a seizure related to trauma or alcohol withdrawal.&#xD;
&#xD;
          8. An active central nervous system infection, demyelinating disease, degenerative&#xD;
             neurological disease, mental retardation, or any central nervous system disease deemed&#xD;
             to be progressive.&#xD;
&#xD;
          9. History of moderate to severe substance or alcohol-use disorder (excluding nicotine or&#xD;
             caffeine) as per DSM-5 criteria within 12 months prior to signing ICF.&#xD;
&#xD;
         10. Subjects who answer &quot;Yes&quot; on the C-SSRS Suicidal Ideation Item 4 (Active Suicidal&#xD;
             Ideation with Some Intent to Act, Without Specific Plan) and whose most recent episode&#xD;
             meeting criteria for this C-SSRS Item 4 occurred within the last 6 months, OR Subjects&#xD;
             who answer &quot;Yes&quot; on the C-SSRS Suicidal Ideation Item 5 (Active Suicidal Ideation with&#xD;
             Specific Plan and Intent).&#xD;
&#xD;
         11. Human immunodeficiency virus seropositive status or acquired immunodeficiency&#xD;
             syndrome, chronic hepatitis B or C.&#xD;
&#xD;
         12. Subject with a positive urine drug screen for illicit drugs or a positive breathalyzer&#xD;
             test for alcohol.&#xD;
&#xD;
         13. Subjects with medically significant abnormal laboratory test results, vital sign&#xD;
             results, or ECG findings.&#xD;
&#xD;
         14. Subjects who received transcranial magnetic stimulation or electroconvulsive therapy&#xD;
             within 60 days of screening.&#xD;
&#xD;
         15. Any condition possibly affecting drug absorption, including bowel resections,&#xD;
             bariatric weight loss surgery, or gastrectomy (this does not include gastric banding).&#xD;
&#xD;
         16. Subjects with difficulty swallowing.&#xD;
&#xD;
         17. Subjects with a history of neuroleptic malignant syndrome.&#xD;
&#xD;
         18. Subject who refuses to abstain from grapefruit-containing foods or beverages, or&#xD;
             Seville orange-containing foods or beverages.&#xD;
&#xD;
        Cohorts 1 Through 5 (Part A) Subjects are excluded from the trial (Cohorts 1 through 5) if&#xD;
        any of the following additional criteria apply:&#xD;
&#xD;
          1. Subjects who have experienced psychosis requiring hospitalization within the 6 months&#xD;
             prior to signing ICF.&#xD;
&#xD;
          2. Subjects who experienced psychosis requiring a change in their antipsychotic&#xD;
             medication (either drug type or dose) within the 3 months prior to signing ICF.&#xD;
&#xD;
          3. Subjects who fulfill any of the following dietary restrictions: • History of chronic&#xD;
             consumption of &gt;400 mg/day of caffeine-containing drinks or food • Refuses to abstain&#xD;
             from caffeine-containing foods or caffeinated beverages for 48 hours prior to Day -1&#xD;
             through Follow up Visit • Refuses to abstain from alcohol from 7 days prior to Day -1&#xD;
             through Follow-up Visit&#xD;
&#xD;
          4. Subjects who have participated in any clinical trial within 60 days prior to signing&#xD;
             ICF.&#xD;
&#xD;
          5. Subjects with a 12-lead ECG demonstrating any of the following:&#xD;
&#xD;
               -  Abnormal ST-T-wave morphologies that may interfere with QT analysis, such as flat&#xD;
                  or poorly defined end of the T wave or prominent U waves&#xD;
&#xD;
               -  Left ventricular hypertrophy&#xD;
&#xD;
               -  QT interval corrected for heart rate QTcF &gt;450 msec&#xD;
&#xD;
               -  QRS interval &gt;110 msec&#xD;
&#xD;
               -  Left or right bundle branch block&#xD;
&#xD;
               -  PR interval &gt;240 msec&#xD;
&#xD;
               -  Heart rate &lt;50 bpm or &gt;90 bpm&#xD;
&#xD;
               -  Second- or third-degree atrioventricular block&#xD;
&#xD;
          6. Systolic blood pressure ≥130 mmHg and/or diastolic blood pressure ≥80 mmHg at&#xD;
             Screening or Day -1, will be taken with subjects in the supine/semi-recumbent&#xD;
             position, or symptomatic hypotension, or orthostatic hypotension, which is defined as&#xD;
             a decrease of ≥20 mmHg in systolic blood pressure and/or a decrease of ≥10 mmHg in&#xD;
             diastolic blood pressure after at least 3 minutes of standing compared with the&#xD;
             immediately previous supine blood pressure. Subjects who are receiving chronic&#xD;
             treatment with antihypertensive medications at Screening are also excluded.&#xD;
&#xD;
        Cohort 6 (Part B) Only Subjects are excluded from trial (Cohort 6 only) if any of the&#xD;
        following additional criteria apply:&#xD;
&#xD;
          1. Subjects who have been hospitalized &gt;14 days for the current episode of schizophrenia&#xD;
             at the time of signing the ICF, excluding hospitalization for psychosocial reasons.&#xD;
&#xD;
          2. Subjects presenting with a first episode of schizophrenia, based on clinical judgment&#xD;
             of the investigator.&#xD;
&#xD;
          3. Subjects with a 12-lead ECG exclusion as in Part A but will allow right bundle branch&#xD;
             block in Part B.&#xD;
&#xD;
          4. Systolic blood pressure &gt;130 mmHg and/or diastolic blood pressure &gt;80 mmHg at&#xD;
             Screening or Day -1 and subjects with orthostatic hypotension, defined as a decrease&#xD;
             of ≥20 mmHg in systolic blood pressure and/or a decrease of ≥10 mmHg in diastolic&#xD;
             blood pressure after at least 3 minutes of standing compared with the average resting&#xD;
             supine/semi-recumbent blood pressure at Screening or Day -1, will be excluded.&#xD;
             Subjects with a heart rate &lt;50 bpm or &gt;90 bpm. Subjects who are receiving chronic&#xD;
             treatment with antihypertensive medications at Screening are also excluded.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Matthew Leoni, MD</last_name>
    <role>Study Director</role>
    <affiliation>Cerevel Therapeutics, LLC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pillar Clinical Research</name>
      <address>
        <city>Bentonville</city>
        <state>Arkansas</state>
        <zip>72712</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Woodlands International Research Group</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72211</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synergy San Diego</name>
      <address>
        <city>Lemon Grove</city>
        <state>California</state>
        <zip>91945</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Collaborative Neuroscience Network, LLC</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <zip>90806</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hassman Research Institute</name>
      <address>
        <city>Marlton</city>
        <state>New Jersey</state>
        <zip>08053</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>October 16, 2019</study_first_submitted>
  <study_first_submitted_qc>October 21, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 23, 2019</study_first_posted>
  <last_update_submitted>July 1, 2021</last_update_submitted>
  <last_update_submitted_qc>July 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schizophrenia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

